Ionis Pharmaceuticals. has filed a patent for administering ISIS 678354 to treat Familial Chylomicronemia Syndrome, Familial Partial Lipodystrophy, and Severe Hypertriglyceridemia by reducing APOCIII RNA or protein levels in human subjects. The method aims to alleviate symptoms such as abdominal pain, fatigue, and pancreatitis. GlobalData’s report on Ionis Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Ionis Pharmaceuticals, Nucleic acid active pharmaceutical ingredient was a key innovation area identified from patents. Ionis Pharmaceuticals's grant share as of January 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.
A patent application (Publication Number: US20240033280A1) discloses a method for treating Familial Chylomicronemia Syndrome (FCS) by reducing APOCIII RNA or protein levels in human subjects. The method involves administering a compound with a specific chemical structure subcutaneously or intrathecally every 4 weeks. The compound, represented by SEQ ID NO: 3, or its salt, is administered in doses of 50 mg or 80 mg to alleviate symptoms of FCS. Additionally, the compound can be a sodium or potassium salt, and a modified oligonucleotide with specific nucleobases, sugar moieties, and internucleoside linkages can also be used for treatment.
Furthermore, the method outlined in the patent application targets severe symptoms associated with FCS, such as elevated chylomicrons and triglyceride levels, abdominal pain, fatigue, cognitive difficulties, diarrhea, pancreatitis, xanthomata, and hepatosplenomegaly. The treatment regimen involves regular subcutaneous administration of the compound every 4 weeks to address these symptoms effectively. The compound's specific chemical structure and mode of administration aim to reduce APOCIII RNA or protein levels, providing relief to individuals suffering from FCS. The patent application emphasizes the importance of addressing these symptoms to improve the quality of life for patients with FCS.
To know more about GlobalData’s detailed insights on Ionis Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
